ライフサイエンスコーパス: recrudescent

1 However, persistent and recrudescent active trachoma in some populations might c

2 Recrudescent and new infections were distinguished by co

3 her wave of commitment is observed following recrudescent asexual parasitemia, and these gametocytes

4 omised control of the acute and the chronic, recrudescent blood-stage infections with P. c.

5 parturition stressors did not lead to overt/recrudescent clinical disease, but intermittent viremia

6 tation at our center to identify factors for recrudescent coccidioidomycosis (despite antifungal prop

7 ntifungal prophylaxis effectively suppressed recrudescent coccidioidomycosis after solid organ transp

8 h quiescent infection, azoles suppressed any recrudescent coccidioidomycosis after transplantation.

9 less than 3 months (P<0.05); one subject had recrudescent disease after two years.

10 ts organ-specific EBOV persistence and fatal recrudescent disease in rhesus macaque survivors after t

11 ersisting life stage responsible for causing recrudescent disease.

12 investigations of two patients who developed recrudescent Ebola virus disease and subsequent fatal me

13 Some patients have persistent or recrudescent fever despite this therapy.

14 saki disease patients who have persistent or recrudescent fever, promising new therapies are under st

15 parasites and fever by day 7, and absence of recrudescent infection by parasites with the same molecu

16 findings are consistent with the origins of recrudescent infection by reactivation from many latentl

17 Among patients who experienced recrudescent infection despite antifungal prophylaxis, A

18 ampylobacteriosis as well as observations of recrudescent infection following treatment with C. jejun

19 ed large pool of cells and sites to rekindle recrudescent infection highlights the challenges in erad

20 cells are thought be the principal source of recrudescent infection, but this estimate is based on pe

21 erapy is associated with a high frequency of recrudescent infection, resulting in treatment failure.

22 les along axons, resulting in characteristic recrudescent infection.

23 ence of a refractory reservoir that may seed recrudescent infection.

24 response may resolve the clinical problem of recrudescent infection.

25 nts with recent SP intake are likely to have recrudescent infections and may need close follow-up if

26 ng mutations of new infections with those of recrudescent infections due to parasites that survived p

27 Recrudescent infections occurred in 4 of 79 patients in

28 Timely responses to recrudescent infections or emerging variants of concern

29 ctericidal levels of antibiotics and lead to recrudescent infections resistant to therapy.

30 mpared with initial treatments, treatment of recrudescent infections was associated with a higher rat

31 Recrudescent infections were associated with the selecti

32 Recrudescent infections were uncommon in both the DHA-PQ

33 strains of the virus and be associated with recrudescent infections.

34 ome phylogenetics successfully discriminated recrudescent iNTS from reinfection, despite a high level

35 ion dynamics in three patients that suffered recrudescent invasive infection caused by the original i

36 simplex virus 1 (HSV-1) most commonly causes recrudescent labial ulcers; however, it is also the lead

37 d those with secondary outcomes [eg, new non-recrudescent malaria infection] were censored on the las

38 lays a key role in artemisinin resistance in recrudescent malaria infections.

39 ion (TPI)' to define foetal infection from a recrudescent maternal infection acquired before pregnanc

40 hosts, and it is associated with a risk for recrudescent microbial growth and development of disease

41 who have recovered from COVID-19, a chronic, recrudescent, or permanent olfactory deficit could be pr

42 related to the number of SNPs accumulated by recrudescent organisms, suggesting that there was little

43 Patients with recrudescent P falciparum infections were more likely to

44 The primary outcome was recrudescent P falciparum parasitaemia within 63 days.

45 Analysis of recrudescent parasites after ELQ or atovaquone monothera

46 In a recent clinical trial for cipargamin, recrudescent parasites emerged, with most having a G358S

47 ith uncomplicated P. falciparum malaria, and recrudescent parasites frequently harbored a treatment-e

48 asite polymorphisms were used to distinguish recrudescent parasites from new infections.

49 Recrudescent parasites had a higher prevalence of kelch1

50 group was uncommon, limiting the analysis of recrudescent parasites.

51 concentrations at baseline compared with non-recrudescent patients, but did not differ significantly

52 After cellular therapy, no patients had recrudescent SARS-CoV-2 infection or COVID-19-related co

53 he acute phase included acute stroke, new or recrudescent seizures, anatomic brain lesions, presence

54 Recrudescent T-cell activity coincided with the presence

55 tation units in high baseline categories and recrudescent TF(1-9) might prolong the attainment of eli

56 immunotherapeutic implications in combating recrudescent toxoplasmosis as well other chronic infecti

57 When only recrudescent treatment failures were considered, the ris

58 w often sepsis readmissions are for relapsed/recrudescent versus new infections.

59 d a large number of R/F viruses representing recrudescent viremia from multiple sources.

60 antiretroviral therapy (cART) and can cause recrudescent viremia if cART is interrupted.

61 emory TFH and FDC-bound virions in promoting recrudescent viremia in the setting of ART cessation is

62 In two of these animals, the recrudescent virus population contained only the vaccine

63 n IL-10R blocking Ab enhanced control of the recrudescent virus.

64 ebounding virus, resulting in restriction of recrudescent viruses and selection for preexisting and e